Research and Clinical Trials on Fluoxetine (Prozac, Sarafem)

By Dr Greg Mulhauser
avatar image

This list of current clinical research trials on Fluoxetine (Prozac, Sarafem) is followed by a short set of abstracts from the most recent research articles published on the drug.

Article Contents

Fluoxetine (Prozac, Sarafem) Clinical Research Trials

From our searchable database at ClinicalTrialsFeeds.org, this list includes all the latest information about clinical trials involving Fluoxetine (Prozac, Sarafem).

 

Get These Clinical Trials as a Newsfeed

Fluoxetine:     Get the Fluoxetine clinical trials feed.    Add the Fluoxetine clinical trials feed to your My Yahoo! page.    Add the Fluoxetine clinical trials feed to your MyMSN page.

Current Research Literature on Fluoxetine (Prozac, Sarafem)

Here are abstracts for some of the latest research articles to have appeared on Fluoxetine (Prozac, Sarafem):

Fluoxetine Improves the Quality of Life in Patients with Poststroke Emotional Disturbances.

Cerebrovasc Dis. 2008 Jul 23; 26(3): 266-271
Choi-Kwon S, Choi J, Kwon SU, Kang DW, Kim JS
Background: Fluoxetine may improve the poststroke emotional disturbances. The purpose of the present study was to evaluate the efficacy of fluoxetine on quality of life (QOL) over time in stroke patients with emotional disturbances. Methods: We studied 152 consecutive stroke patients (mean age, 58 years) who had either poststroke depression (PSD), emotional incontinence (PSEI) or anger proneness (PSAP) at an average of 14 months (range = 3-28) after the onset of stroke. The Korean version of SF-36 was used to assess the QOL. The presence of PSD, PSEI and PSAP was also determined with a standardized questionnaire. The subjects were given either 20 mg/day of fluoxetine (n = 76) or placebo (n = 76) for 3 months. Follow-up evaluations were done at 3, 6 and 12 months after the beginning of the treatment. Results: The score in the mental health domain was significantly higher in the fluoxetine group than in the placebo group at the 3-, 6- and 12-month follow-ups. The scores in the general health (p < 0.05) and social functioning (p < 0.05) domains were also significantly higher in the fluoxetine than in the placebo group at 12 months of follow up even if there was no definitive improvement in PSD, PSEI and PSAP at this time. Conclusions: Fluoxetine is effective in improving QOL, particularly so in the mental health subdomain. Our results suggest that fluoxetine may be used to improve the QOL of stroke patients with emotional disturbances.

Neuropharmacology of human appetite expression.

Dev Disabil Res Rev. 2008 Jul 21; 14(2): 158-164
Halford JC, Harrold JA
The regulation of appetite relies on the integration of numerous episodic (meal) and tonic (energy storage) generated signals in energy regulatory centres within the central nervous system (CNS). These centers provide the pharmacological potential to modify human appetite (hunger and satiety) to increase or decrease caloric intake, or to normalize aberrant eating behavior. With regard to obesity, the satiety enhancing anti-obesity drug sibutramine has proved effective at reducing body weight. Additionally, the endocannabinoid CB(1) antagonist rimonabant has recently been approved for use in Europe (but not in the US). A 5-HT(2C) agonist lorcaserin is also currently undergoing large-scale clinical trials, but the effect of the drug on human appetite is unknown as yet. Appetite enhancing drugs such as magestrol acetate and dronabiol are currently used to promote weight gain. Finally, sibutramine, selective serotonergic reuptake inhibitors such as fluoxetine and some anti-epileptic drugs have all been used to normalise aberrant eating behaviour. All these drugs act by modifying the expression of human appetite. An assessment of a drug's effectson caloric intake and feelings of hunger and satiety is necessary before they can be considered for clinical use. (c) 2008 Wiley-Liss, Inc. Dev Disabil Res Rev 2008;14:158-164.

Why we should use simpler models if the data allow this: relevance for ANOVA designs in experimental biology.

BMC Physiol. 2008 Jul 21; 8(1): 16
Lazic SE
ABSTRACT: BACKGROUND: Analysis of variance (ANOVA) is a common statistical technique in physiological research, and often one or more of the independent/predictor variables such as dose, time, or age, can be treated as a continuous, rather than a categorical variable during analysis--even if subjects were randomly assigned to treatment groups. While this is not common, there are a number of advantages of such an approach, including greater statistical power due to increased precision, a simpler and more informative interpretation of the results, greater parsimony, and transformation of the predictor variable is possible. RESULTS: An example is given from an experiment where rats were randomly assigned to receive either 0, 60, 180, or 240 mg/L of fluoxetine in their drinking water, with performance on the forced swim test as the outcome measure. Dose was treated as either a categorical or continuous variable during analysis, with the latter analysis leading to a more powerful test (p = 0.021 vs. p = 0.159). This will be true in general, and the reasons for this are discussed. CONCLUSIONS: There are many advantages to treating variables as continuous numeric variables if the data allow this, and this should be employed more often in experimental biology. Failure to use the optimal analysis runs the risk of missing significant effects or relationships.

Antidepressant-Associated Mood Elevations in Bipolar II Disorder Compared With Bipolar I Disorder and Major Depressive Disorder: A Systematic Review and Meta-Analysis.

J Clin Psychiatry. 2008 Jul 15; e1-e13
Bond DJ, Noronha MM, Kauer-Sant'anna M, Lam RW, Yatham LN
OBJECTIVE: Antidepressant-associated manic and hypomanic episodes have been reported in bipolar I disorder but are rare in major depressive disorder (MDD). Several lines of evidence suggest that bipolar II disorder is a distinct illness from bipolar I disorder and MDD. The risk of antidepressant-associated mood elevations (AAME) in bipolar II disorder relative to bipolar I disorder and MDD is unknown. DATA SOURCES: We conducted a computer-aided MEDLINE search encompassing the dates 1949 to February 2008, using the keywords antidepressant and mania, antidepressant and hypomania, antidepressant and bipolar, fluoxetine and bipolar, fluvoxamine and bipolar, sertraline and bipolar, paroxetine and bipolar, citalopram and bipolar, escitalopram and bipolar, venlafaxine and bipolar, mirtazapine and bipolar, bupropion and bipolar, monoamine oxidase inhibitor and bipolar, phenelzine and bipolar, tranylcypromine and bipolar, tricyclic and bipolar, imipramine and bipolar, amitriptyline and bipolar, nortriptyline and bipolar, and desipramine and bipolar. STUDY SELECTION: All prospective English-language studies, including randomized, controlled trials (RCTs), open-label studies, and naturalistic treatment reports, were eligible for inclusion. We located 13 studies, including 7 RCTs, that reported rates of antidepressant-associated mood elevations in bipolar I disorder versus bipolar II disorder, and 5, including 4 RCTs, that reported rates in bipolar II disorder versus MDD. DATA EXTRACTION: Data were combined to estimate mean switch rates and subjected to meta-analysis to determine the relative risks of antidepressant-associated mood elevations in bipolar I disorder versus bipolar II disorder and in bipolar II disorder versus MDD. DATA SYNTHESIS: The mean rates of antidepressant-associated mood elevations in studies comparing bipolar I disorder and bipolar II disorder were 14.2% and 7.1%, respectively, in acute trials (less than 16 weeks), and 23.4% and 13.9%, respectively, in maintenance studies. The mean rates in reports comparing bipolar II disorder and MDD were 8.1% and 1.5%, respectively, in acute trials, and 16.5% and 6.0%, respectively, in maintenance studies. The relative risk (RR) of antidepressant-associated mood elevations was greater in bipolar I disorder than bipolar II disorder (RR = 1.78, 95% CI = 1.24 to 2.58, p = .002), and higher in bipolar II disorder than MDD (RR = 2.77, 95% CI = 1.26 to 6.09, p = .01). Mood elevations occurred almost exclusively into hypomania in MDD and bipolar II disorder, while patients with bipolar I disorder experienced manias and hypomanias with similar frequencies. CONCLUSIONS: The risk of antidepressant-associated mood elevations in bipolar II disorder is intermediate between that in bipolar I disorder and MDD.

Desipramine or glutamate antagonists synergized the antidepressant-like actions of intra-nucleus accumbens infusions of minocycline in male Wistar rats.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jul 1;
Molina-Hernández M, Téllez-Alcántara NP, Pérez-García J, Olivera-Lopez JI, Jaramillo-Jaimes MT
Minocycline produces antidepressant-like actions in male rats tested in the forced swimming test (FST) and synergizes with several glutamate receptor antagonists. However, the limbic regions implicated in the antidepressant-like actions of minocycline are unknown. The objective of the present study was to test the potential antidepressant activity of nucleus accumbens infusions of minocycline alone or combined with antidepressant drugs or with several glutamate receptor antagonists, using the time-sampling method in the FST. The results show that intra-NAcc infusions of minocycline reduced immobility (1.0 microg, P < 0.05; 1.5 microg, P < 0.05) by increasing climbing (1.0 microg, P < 0.05; 1.5 microg, P < 0.05) in the FST. Likewise, systemic injections of desipramine (P < 0.05), fluoxetine (P < 0.05) or several glutamate receptor antagonists: EMQMCM (P < 0.05), MTEP (P < 0.05) or dizocilpine (P < 0.05) combined with intra-nucleus accumbens infusions of vehicle produced antidepressant-like actions. The subthreshold dose of intra-nucleus accumbens infusions of minocycline combined with systemic injections of subthreshold doses of desipramine (P < 0.05) or EMQMCM (P < 0.05) or MTEP (P < 0.05) or dizocilpine (P < 0.05) produced antidepressant-like actions. It is concluded that intra-NAcc infusions of minocycline alone or combined with systemic injections of desipramine or with systemic injections of several glutamate receptor antagonists produced antidepressant-like actions in the FST.

 

This page was last reviewed by Dr Greg Mulhauser, Friday, 4 July 2008.

The URL of this page is:
http://counsellingresource.com/medications/trials-and-research/fluoxetine-research.html